ALS Drug Development: Reflections from the Past and a Way Forward

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 516-527

  Aggarwal, Swati ^a   Cudkowicz, Merit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; clinical trial; conduct; critical review; trial design

Indexed keywords

ALPHA TOCOPHEROL; AMPA RECEPTOR AGONIST; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARIMOCLOMOL; ARUNDIC ACID; CALCIUM CHANNEL STIMULATING AGENT; CEFTRIAXONE; CELECOXIB; CHOLINERGIC RECEPTOR STIMULATING AGENT; CREATINE; DEXTROMETHORPHAN; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; LAMOTRIGINE; MEMANTINE; MINOCYCLINE; NEW DRUG; NIMODIPINE; NORPHENAZONE; OMIGAPIL; PRAMIPEXOLE; RILUZOLE; SELEGILINE; TALAMPANAL; TOPIRAMATE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; ARTICLE; CHROMOSOME 21; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG DESIGN; FAMILY HISTORY; FATIGUE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; MUSCLE LENGTH; MUSCLE STRENGTH; MUSCLE TRAINING; NEUROPATHOLOGY; NONHUMAN; OFF LABEL DRUG USE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; RILUZOLE; TREATMENT OUTCOME;

EID: 53049105819     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.002     Document Type: Article

References (69)

1. Charcot J., and Joffroy A. Deux cas d'atrophie musculaire progressive. Arch Physiol 2 (1869) 354-367
2. Phukan J., Pender N.P., and Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 6 (2007) 994-1003
3. Hammad M., Silva A., Glass J., Sladky J.T., and Benatar M. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 69 (2007) 2236-2242
4. Mitsumoto H., Chad D., and Pioro E. Amyotrophic lateral sclerosis (1998), Oxford Press, New York
5. McGuire V., Longstreth Jr. W., Koepsell T., and van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 47 (1996) 571-573
6. Rowland L.P. Ten central themes in a decade of ALS research. Adv Neurol 56 (1991) 3-23
7. Haverkamp L.J., Appel V., and Appel S.H. Natural history of amyotrophic lateral sclerosis in a database population validation of a scoring system and a model for survival prediction. Brain 118 (1995) 707-719
8. Bowling A.C., Schulz J.B., Brown Jr. R.H., and Beal M.F. Superoxide dismutase activity, oxidative damage and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61 (1993) 2322-2325
9. Valdmanis P.N., and Rouleau G.A. Genetics of familial amyotrophic lateral sclerosis. Neurology 70 (2008) 144-152
10. Al-Chalabi A., Enayat Z., Bakker M., et al. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet 347 (1996) 159-160
11. Mui S., Rebeck G., McKenna-Yasek D., Hyman B., and Brown R. Apolipoprotein E E4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol 38 (1995) 460-463
12. Orrell R., King A., Lane R., and de Belleroche J. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. J Neurol Sci 132 (1995) 126-128
13. Giess R., Goetz R., Schrank B., Ochs G., Sendtner M., and Toyka K. Potential implications of a ciliary neurotrophic factor gene mutation in a German population of patients with motor neuron disease. Muscle Nerve 21 (1998) 236-238
14. Lin C., Bristol L., Jin L., et al. Aberrrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20 (1998) 589-602
15. Trotti D., Rolfs A., Danbolt N., Brown R., and Hediger M. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 2 (1999) 427-433
16. Lambrechts D., Storkebaum E., Morimoto M., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (2003) 383-394
17. Subramanian V., Crabtree B., and Acharya K.R. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum Mol Genet 17 (2008) 130-149
18. Cronin S., Greenway M.J., Prehn J.H., and Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78 (2007) 984-986
19. Al-Chalabi A., Hansen V.K., Simpson C.L., et al. Variants in the ALS2 gene are not associated with sporadic amyotrophic lateral sclerosis. Neurogenetics 4 (2003) 221-222
20. Piepers S., Van Den Berg J.-P., Kalmijn S., et al. Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a review of the literature. Amyotroph Lateral Scler 7 (2006) 195-200
21. Mazzini L., Corra T., Zaccala M., Mora G., Del Piano M., and Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 242 (1995) 695-698
22. Bello-Haas V.D., Florence J.M., Kloos A.D., et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 68 (2007) 2003-2007
23. Drory V.E., Goltsman E., Goldman Reznik J., Mosek A., and Korczyn A.D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 191 (2001) 133-137
24. Camu W., and Henderson C. Rapid purification of embryonic rat motoneurons: an in vitron model for studying MND/ALS pathogenesis. J Neurol Sci 124 suppl (1994) 73-74
25. Vandenberghe W., Van Den Bosch L., and Robberecht W. Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. Brain Res 807 (1998) 1-10
26. Rothstein J.D., Lin L., Dykes-Hoberg M., and Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow motor neuron toxicity. Proc Natl Acad Sci U S A 90 (1993) 6591-6595
27. Menzies F.M., Cookson M.R., Taylor R.W., et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 125 pt 7 (2002) 1522-1533
28. Elroy-Stein O., Bernstein Y., and Groner Y. Overproduction of human Cu/Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. Embo J 5 (1986) 615-622
29. Wong P.C., Pardo C.A., Borchelt D.R., et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116
30. Gurney M.E., Fleck T.J., Himes C.S., and Hall E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50 (1998) 62-66
31. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group. N Engl J Med 330 (1994) 585-591
32. Lacomblez L., Bensimon G., Leigh P., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 (1996) 1425-1431
33. Leach M.J., Marden C.M., and Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug.II. Neurochemical studies on the mechanism of action. Epilepsia 27 (1986) 490-497
34. Skradski S., and White H. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41 suppl 1 (2000) S45-S47
35. Gurney M., Cutting F., Zhai P., et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial ALS. Ann Neurol 39 (1996) 147-157
36. Smith R.A., Miller T.M., Yamanaka K., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116 (2006) 2290-2296
37. Ralph G.S., Radcliffe P.A., Day D.M., et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11 (2005) 429-433
38. Locatelli F., Corti S., Papadimitriou D., et al. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann Neurol 62 (2007) 81-92
39. Urushitani M., Ezzi S.A., and Julien J.-P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 104 (2007) 2495-2500
40. Traynor B.J., Codd M.B., Corr B., et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House Diagnostic Criteria: a population-based study. Arch Neurol 57 (2000) 1171-1176
41. Traynor B.J., Alexander M., Corr B., Frost E., Mahon L., and Hardiman O. Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000. ALS 2 suppl 2 (2001) 43-44 (abstract)
42. Turner M.R., Bakker M., Sham P., Shaw C.E., Leigh P.N., and Al-Chalabi A. The King's database 1990-2000: an analysis of the effect on survival of interventions in ALS 2 suppl 2 (2001) 43 (abstract)
43. Brooks B.R., Belden D.S., Roelke K., et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - motor neuron disease (MND) patients with disease onset before and since 1996 is identical: A clinic-based epidemiologic study. ALS 2 suppl 2 (2001) 60-61 (abstract)
44. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61 (2003) 456-464
45. Shefner J.M., Cudkowicz M.E., Schoenfeld D., et al. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology 63 (2004) 1656-1661
46. Cudkowicz M., Shefner J., Schoenfeld D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60 (2006) 22-31
47. Miller R., Bradley W., Cudkowicz M., et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 69 (2007) 776-784
48. Desnuelle C., Dib M., Garrel C., and Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 9-18
49. Gordon P.H., Moore D.H., Miller R.G., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6 (2007) 1045-1053
50. Gordon P.H., Moore D.H., Gelinas D.F., et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62 (2004) 1845-1847
51. Groeneveld G.J., Veldink J.H., van der Tweel I., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53 (2003) 437-445
52. Tabrizi S.J., Blamire A.M., Manners D.N., et al. High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. Neurology 64 (2005) 1655-1656
53. Drachman D., Frank K., Dykes-Hoberg M., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52 (2002) 771-778
54. Gredal O., Werdelin L., Bak S., et al. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand 96 (1997) 8-13
55. Graf M., Ecker D., Horowski R., et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 112 (2005) 649-660
56. Lange D.J., Murphy P.L., Diamond B., et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55 (1998) 93-96
57. Miller R.G., Shepherd R., Dao H., et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 6 (1996) 101-104
58. Miller R.G., Smith S.A., Murphy J.R., et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19 (1996) 511-515
59. Meininger V., Bensimon G., Bradley W.G., et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 5 (2004) 107-117
60. Milane A., Fernandez C., Vautier S., Bensimon G., Meininger V., and Farinotti R. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem 103 (2007) 164-173
61. Schoenfeld D.A., and Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler 9 (2008) 16-23
62. Lyall R.A., Donaldson N., Polkey M.I., Leigh P.N., and Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124 (2001) 2000-2013
63. Fitting J., Paillex R., Hirt L., Aebischer P., and Schluep M. Sniff nasal pressure, a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 46 (1999) 887-893
64. Meininger V., Asselain B., Guillet P., et al. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 66 (2006) 88-92
65. Testa D., Lovati R., Ferrarini M., Salmoiraghi F., and Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord 5 (2004) 208-212
66. Czaplinski A., Yen A.A., Simpson E.P., and Appel S.H. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?. Arch Neurol 63 (2006) 1139-1143
67. Miller R., Moore D.H., Young L., and Group W.S. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 47 (1996) 1383-1388
68. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52 (1999) 1427-1433
69. Miller R.G., Moore D.H., Gelinas D.F., et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56 (2001) 843-848